Kanamori Y, Kigawa J, Minagawa Y, Irie T, Oishi T, Shimada M, Takahashi M, Nakamura T, Sato K, Terakawa N
Department of Obstetrics and Gynaecology, Tottori University School of Medicine, Yonago, Japan.
Eur J Cancer. 1998 Oct;34(11):1802-6. doi: 10.1016/s0959-8049(98)00199-3.
A new recombinant adenovirus carrying a wild-type p53 gene (AxCAp53) was developed and the combination effect of p53 gene transfer and cis-diamminedichloroplatinum (II) (CDDP) was examined in an ovarian cancer cell line, SK-OV-3, with deletion of the p53 gene. AxCAp53 showed a high efficiency of gene transduction and increased sensitivity to CDDP in the SK-OV-3 cells. It was found that the sensitivity of the cells to CDDP correlated with the amount of infectious units of virus per cell of AxCAp53 which correlated with p53 protein expression. The results suggest that the combination of CDDP and AxCAp53 may be a potential strategy for the therapy of CDDP-resistant ovarian cancer.
一种携带野生型p53基因的新型重组腺病毒（AxCAp53）被研发出来，并在p53基因缺失的卵巢癌细胞系SK-OV-3中检测了p53基因转移与顺二氯二氨铂（II）（CDDP）的联合效应。AxCAp53在SK-OV-3细胞中显示出高效的基因转导能力，并增强了对CDDP的敏感性。研究发现，细胞对CDDP的敏感性与AxCAp53每个细胞的感染单位数量相关，而这又与p53蛋白表达相关。结果表明，CDDP与AxCAp53联合使用可能是治疗耐CDDP卵巢癌的一种潜在策略。
